Becton, Dickinson and Company $BDX Shares Bought by AGF Management Ltd.

AGF Management Ltd. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 29.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,940 shares of the medical instruments supplier’s stock after buying an additional 5,004 shares during the period. AGF Management Ltd.’s holdings in Becton, Dickinson and Company were worth $3,779,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the first quarter worth $26,000. Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $31,000. Bank of Jackson Hole Trust grew its holdings in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the period. WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $36,000. Finally, CVA Family Office LLC raised its holdings in Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 97 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday. Jefferies Financial Group decreased their price objective on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a report on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Stock Up 0.3%

Shares of NYSE BDX opened at $177.88 on Monday. The stock has a market cap of $50.99 billion, a P/E ratio of 31.99, a PEG ratio of 1.42 and a beta of 0.25. The business’s fifty day simple moving average is $186.77 and its 200-day simple moving average is $182.15. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be paid a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s payout ratio is currently 71.36%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,249 shares of company stock worth $231,358. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.